Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (42)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  3. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119

    HIV Medicine, Vol. 24, Núm. 8, pp. 933-937

  4. Incidence of Anal Cancer and Related Risk Factors in HIV-Infected Patients Enrolled in the National Prospective Spanish Cohort CoRIS

    Diseases of the Colon and Rectum, Vol. 66, Núm. 12, pp. E1186-E1194

  5. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  6. Randomized Clinical Trial of the Need for Antibiotic Treatment for Low-Risk Catheter-Related Bloodstream Infection Caused by Coagulase-Negative Staphylococci

    Antibiotics, Vol. 12, Núm. 5

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis

    Clinical Microbiology and Infection

  2. Mortality in Perinatally HIV-infected Adolescents after Transition to Adult Care in Spain

    Pediatric Infectious Disease Journal, Vol. 40, Núm. 4, pp. 347-350

  3. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

  4. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial

    Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305

  3. Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients

    Scientific Reports, Vol. 10, Núm. 1

  4. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344